Cefepime–Taniborbactam in Complicated Urinary Tract Infection

In patients with complicated urinary tract infection, clinical and microbiologic treatment success was significantly better with cefepime–taniborbactam (β-lactam and β-lactamase inhibitor) than with meropenem.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2024-02, Vol.390 (7), p.611-622
Hauptverfasser:	Wagenlehner, Florian M., Gasink, Leanne B., McGovern, Paul C., Moeck, Greg, McLeroth, Patrick, Dorr, MaryBeth, Dane, Aaron, Henkel, Tim
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intravenous Adult Adverse events Aged Aging Aging General Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - adverse effects Anti-Bacterial Agents - therapeutic use Antibiotics Bacteremia Bacteremia - drug therapy Bacteremia - microbiology Bacterial Infections beta-Lactamases - administration & dosage beta-Lactamases - adverse effects beta-Lactamases - therapeutic use Borinic Acids - administration & dosage Borinic Acids - adverse effects Borinic Acids - therapeutic use Carbapenems Carboxylic Acids - administration & dosage Carboxylic Acids - adverse effects Carboxylic Acids - therapeutic use Cefepime Cefepime - administration & dosage Cefepime - adverse effects Cefepime - therapeutic use Clinical Medicine Clinical Medicine General Clinical trials Constipation Diarrhea Drug dosages Drug Resistance, Bacterial Drug Therapy, Combination Enterobacterales Enzymes Geriatrics Hospital-Based Clinical Medicine Hospitalization Humans Infectious Disease Infectious Disease General Meropenem Meropenem - administration & dosage Meropenem - adverse effects Meropenem - therapeutic use Microbial Sensitivity Tests Middle Aged Multidrug resistance Nephrology Outpatient-Based Clinical Medicine Pathogens Patient safety Patients Pharmaceuticals Prostate Disease Prostate Disease General Pseudomonas aeruginosa Public health Pyelonephritis Pyelonephritis - drug therapy Pyelonephritis - microbiology Success Urinary tract Urinary tract diseases Urinary tract infections Urinary Tract Infections - drug therapy Urinary Tract Infections - microbiology Urogenital system Urology UTI β Lactamase β-Lactam antibiotics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In patients with complicated urinary tract infection, clinical and microbiologic treatment success was significantly better with cefepime–taniborbactam (β-lactam and β-lactamase inhibitor) than with meropenem.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2304748